GlassScriptPhysician profile
Shannon S Hagan
NPI 1255747143
$1,076.39
in general payments reported to CMS, 2019-2025
23 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $90.13 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $149.62 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $139.22 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $106.90 | 2022-2025 | Freestyle Libre 3 |
| Averitas Pharma INC. | $68.33 | 2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $64.36 | 2025 | Gvoke Hypopen |
| Novo Nordisk INC | $55.09 | 2025 | Wegovy |
| Cequr Corporation | $50.68 | 2025 | Cequr Simplicity |
| Tolmar, INC. | $49.90 | 2025 | Jatenzo |
| Ibsa Pharma INC. | $47.83 | 2025 | Tirosint, Flector, Licart |
| Beta Bionics, INC. | $43.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $37.88 | 2025 | Yorvipath |
| Lilly USA, LLC | $37.42 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.01 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $27.10 | 2025 | |
| Madrigal Pharmaceuticals | $25.16 | 2025 | Rezdiffra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $22.23 | 2025 | Isturisa |
| Radius Health, INC. | $22.08 | 2025 | Tymlos |
| Soleno Therapeutics, INC. | $19.76 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $18.47 | 2025 | Twiist |
| Amgen INC. | $16.26 | 2025 | Evenity |
| Glaxosmithkline, LLC. | $15.24 | 2025 | Arexvy, Shingrix |
| Antares Pharma, INC. | $14.98 | 2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $13.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Hagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.